Find coverage of the latest original articles on Lupus, focusing on those with data on therapeutic interventions and those that have clinical impact.
This activity is supported by an educational grant from AstraZeneca.
Daily oral upadacitinib 30 mg and ABBV-599 high dose (elsubrutinib 60 mg QD + upadacitinib 30 mg) were effective in multiple outcome measures including disease activity, flares, time to first flare, and joint counts.
Front Immunol. 2023 14:1200732 DOI: 10.3389/fimmu.2023.1200732
Using data from a longitudinal cohort of SLE patients of Chinese origin, the authors identified risk factors for LN and developed a prediction model, RIFLE-LN, which demonstrated good performance in a testing cohort of 270 patients.
